{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:16:06Z","timestamp":1778580966128,"version":"3.51.4"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","funder":[{"name":"National Key Research and Development Program of China","award":["2020YFC2008306"],"award-info":[{"award-number":["2020YFC2008306"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To examine the pharmacokinetics of lacosamide (LCM) in Chinese children and adults with epilepsy and to establish a population pharmacokinetic model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A one-compartment model with first-order absorption and elimination was constructed using 482 plasma samples from 391 individuals. Nonlinear mixed-effects modeling accounted for intraindividual and interindividual variabilities. Covariate effects were evaluated through forward inclusion and backward elimination, and the model performance was validated using goodness-of-fit plots and visual predictive checks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The final population pharmacokinetic (PPK) model indicated that a higher body weight and lower urea levels were associated with increased LCM clearance (CL). Coadministration of phenobarbital or carbamazepine resulted in a 1.42-fold increase in LCM CL. The absorption rate constant was fixed at 0.13, with typical values of CL and apparent volume of distribution (V\n                      <jats:sub>d<\/jats:sub>\n                      ) being 1.19 L\/h and 9.95 L, respectively. The association between pharmacokinetic parameters and covariates was quantified as follows: \n                                    \n                                       \n                                    \n                                  (IND1 = 0.35 if comedicated with phenobarbital or carbamazepine; otherwise = 0).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The PPK model developed in this study plays a pivotal role in optimizing and personalizing LCM therapy for patients with epilepsy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001385","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T12:01:52Z","timestamp":1758110512000},"page":"358-365","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetic Model of Lacosamide in Chinese Children and Adults with Epilepsy"],"prefix":"10.1097","volume":"48","author":[{"given":"Ruoyun","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; and"},{"name":"Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; and"},{"name":"Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; and"},{"name":"Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghui","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; and"},{"name":"Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"R1-20260508","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","year":"2019","journal-title":"Lancet Neurol"},{"key":"R2-20260508","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12883-015-0494-y","article-title":"The economic impact of epilepsy: a systematic review","volume":"15","author":"Allers","year":"2015","journal-title":"BMC Neurol"},{"key":"R3-20260508","doi-asserted-by":"crossref","first-page":"1164902","DOI":"10.3389\/fphar.2023.1164902","article-title":"Therapeutic drug monitoring of lacosamide among children: is it helpful?","volume":"14","author":"Kohn","year":"2023","journal-title":"Front Pharmacol"},{"key":"R4-20260508","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40261-015-0277-7","article-title":"Effect of age and sex on lacosamide pharmacokinetics in healthy adult subjects and adults with focal epilepsy","volume":"354","author":"Schaefer","year":"2015","journal-title":"Clin Drug Investig"},{"key":"R5-20260508","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus Guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R6-20260508","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/FTD.0000000000000599","article-title":"Pharmacokinetic variability and clinical use of lacosamide in children and adolescents in Denmark and Norway","volume":"41","author":"Larsen Burns","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R7-20260508","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1111\/epi.17399","article-title":"Effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy","volume":"63","author":"Ahn","year":"2022","journal-title":"Epilepsia"},{"key":"R8-20260508","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.7150\/ijms.107660","article-title":"Dai H therapeutic drug monitoring for lacosamide in Chinese pediatric patients with epilepsy: focus on clinical effectiveness, tolerability and drug interactions","volume":"22","author":"Mao","year":"2025","journal-title":"Int J Med Sci"},{"key":"R9-20260508","doi-asserted-by":"crossref","first-page":"109601","DOI":"10.1016\/j.yebeh.2023.109601","article-title":"How to handle a missed or delayed dose of lacosamide in pediatric patients with epilepsy? A mode-informed individual dosing","volume":"151","author":"Wang","year":"2024","journal-title":"Epilepsy Behav"},{"key":"R10-20260508","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/jcph.1840","article-title":"Use of real-world data and pharmacometric modeling in support of lacosamide dosing in pediatric patients under 4 years of age","volume":"61","author":"Lukka","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"R11-20260508","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2018.10.011","article-title":"Modeling and simulation for the evaluation of dose adaptation rules of intravenous lacosamide in children","volume":"149","author":"Winkler","year":"2019","journal-title":"Epilepsy Res"},{"key":"R12-20260508","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/jcph.1340","article-title":"Population pharmacokinetics of adjunctive lacosamide in pediatric patients with epilepsy","volume":"59","author":"Winkler","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"R13-20260508","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1124\/dmd.108.021279","article-title":"Houston JB Comparative analysis of CYP3A heteroactivation by steroid hormones and flavonoids in different in vitro systems and potential in vivo implications","volume":"36","author":"Henshall","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R14-20260508","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1124\/jpet.102.047530","article-title":"In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine","volume":"305","author":"Egnell","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R15-20260508","first-page":"4890287","article-title":"Acute uric acid nephropathy following epileptic seizures: case report and review","volume":"2019","author":"Patel","year":"2019","journal-title":"Case Rep Rev Case Rep Nephrol"},{"key":"R16-20260508","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R17-20260508","first-page":"31","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"R18-20260508","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.metabol.2005.11.004","article-title":"Van gaal L Body surface area in normal-weight, overweight, and obese adults. A comparison study","volume":"55","author":"Verbraecken","year":"2006","journal-title":"Metab Clin Exp"},{"key":"R19-20260508","doi-asserted-by":"crossref","first-page":"115437","DOI":"10.1016\/j.jpba.2023.115437","article-title":"Simultaneous determination of 24 antiepileptic drugs and their active metabolites in human plasma by UHPLC-MS\/MS","volume":"232","author":"Jiang","year":"2023","journal-title":"J Pharm Biomed Anal"},{"key":"R20-20260508","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/epi.12085","article-title":"Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers","volume":"54","author":"Cawello","year":"2013","journal-title":"Epilepsia"},{"key":"R21-20260508","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/jps.23574","article-title":"A pharmacokinetic standard for babies and adults","volume":"102","author":"Holford","year":"2013","journal-title":"J Pharm Sci"},{"key":"R22-20260508","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/FTD.0000000000000100","article-title":"Population pharmacokinetics of valproic acid in adult Chinese epileptic patients and its application in an individualized dosage regimen","volume":"37","author":"Lin","year":"2015","journal-title":"Ther Drug Monitor"},{"key":"R24-20260508","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1042\/CS20160203","article-title":"Urea, a true uremic toxin: the empire strikes back","volume":"131","author":"Lau","year":"2017","journal-title":"Clin Sci"},{"key":"R25-20260508","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bios.2018.09.067","article-title":"Determination of urea with special emphasis on biosensors: a review","volume":"123","author":"Pundir","year":"2019","journal-title":"Biosens Bioelectron"},{"key":"R26-20260508","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40560-023-00700-4","article-title":"Lacosamide dosing in patients receiving continuous renal replacement therapy","volume":"11","author":"Chaijamorn","year":"2023","journal-title":"J Intensive Care"},{"key":"R27-20260508","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s40262-013-0080-7","article-title":"Impact of impaired renal function on the pharmacokinetics of the antiepileptic drug lacosamide","volume":"52","author":"Cawello","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"R28-20260508","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1002\/phar.2063","article-title":"Lacosamide pharmacokinetics in a critically ill patient receiving continuous venovenous hemofiltration","volume":"38","author":"Franquiz","year":"2018","journal-title":"Pharmacotherapy"},{"key":"R29-20260508","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/0897190018803765","article-title":"Lacosamide pharmacokinetics in a critically ill patient during continuous renal replacement therapy","volume":"33","author":"Wieruszewski","year":"2020","journal-title":"J Pharm Pract"},{"key":"R31-20260508","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/FTD.0000000000001278","article-title":"Lacosamide pharmacokinetics and retention in Japanese patients with epilepsy: a retrospective Study on the influence of Age, comedications, and cytochrome P450 2C19 polymorphism","volume":"47","author":"Yamamoto","year":"2025","journal-title":"Ther Drug Monit"},{"key":"R32-20260508","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/FTD.0b013e318290eacc","article-title":"Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs","volume":"35","author":"Contin","year":"2013","journal-title":"Ther Drug Monit"},{"key":"R33-20260508","doi-asserted-by":"crossref","first-page":"949783","DOI":"10.3389\/fped.2022.949783","article-title":"Plasma lacosamide monitoring in children with epilepsy: focus on reference therapeutic range and influencing factors","volume":"10","author":"Li","year":"2022","journal-title":"Front Pediatr"},{"key":"R34-20260508","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1684\/epd.2014.0714","article-title":"Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs","volume":"16","author":"Zaccara","year":"2015","journal-title":"Epileptic Disord"},{"key":"R35-20260508","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1177\/0091270011426875","article-title":"No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers","volume":"52","author":"Cawello","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"R36-20260508","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/FTD.0000000000000051","article-title":"Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs","volume":"36","author":"Markoula","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R37-20260508","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000336774","article-title":"Pharmacokinetics of lacosamide in healthy Korean male volunteers","volume":"89","author":"Kim","year":"2012","journal-title":"Pharmacology"},{"key":"R38-20260508","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/FTD.0000000000000627","article-title":"Improving therapeutic decisions: pharmacodynamic monitoring as an integral part of therapeutic drug monitoring","volume":"41","author":"Shipkova","year":"2019","journal-title":"Ther Drug Monit"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:43:29Z","timestamp":1778579009000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001385","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"2025-06-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}